APM
Aptorum Group Ltd
$
1.970
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.2488
Open
2.230
VWAP
2.08
Vol
506.62K
Mkt Cap
14.07M
Low
1.9301
Amount
1.05M
EV/EBITDA(TTM)
--
Total Shares
5.47M
EV
7.16M
EV/OCF(TTM)
--
P/S(TTM)
--
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
Show More
Valuation Metrics
The current forward P/E ratio for Aptorum Group Ltd (APM.O) is 0.03, compared to its 5-year average forward P/E of -1.54. For a more detailed relative valuation and DCF analysis to assess Aptorum Group Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.54
Current PE
0.03
Overvalued PE
0.06
Undervalued PE
-3.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.69
Current EV/EBITDA
0.48
Overvalued EV/EBITDA
6.72
Undervalued EV/EBITDA
-14.09
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
22.81
Current PS
0.06
Overvalued PS
54.49
Undervalued PS
-8.87
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
APM News & Events
Events Timeline
2025-08-21 (ET)
2025-08-21
07:10:13
Aptorum Group and DiamiR Receive Approval for APOE Genotyping Test in New York State
2025-08-04 (ET)
2025-08-04
08:18:11
Aptorum Group regains compliance with Nasdaq minimum bid price rule
2025-07-16 (ET)
2025-07-16
08:40:11
Aptorum Group, DiamiR Biosciences entered definitive merger agreement
Sign Up For More Events
Sign Up For More Events
News
4.5
08-22BenzingaDow Rises More Than 300 Points; BJ's Wholesale Stock Declines Following Q2 Earnings Report
9.5
08-22BenzingaEpicQuest Education Shares Surge Over 81%; Check Out 20 Stocks Making Moves in Premarket Trading
4.5
08-22BenzingaStock Market Update: Nasdaq, Dow, and S&P 500 Futures Climb Before Powell's Address at Jackson Hole—EpicQuest, Zoom, and Azitra Stocks Highlighted
Sign Up For More News
People Also Watch
OMH
Ohmyhome Ltd
1.250
USD
+5.49%
ALUR
Allurion Technologies Inc
2.170
USD
-2.25%
POLA
Polar Power Inc
2.060
USD
-2.83%
POAI
Predictive Oncology Inc
0.875
USD
-4.37%
LDWY
Lendway Inc
5.510
USD
+2.23%
CYCN
Cyclerion Therapeutics Inc
2.470
USD
-3.93%
MGRX
Mangoceuticals Inc
2.360
USD
+4.89%
GRNQ
GreenPro Capital Corp
1.450
USD
-6.45%
GMM
Global Mofy AI Ltd
2.220
USD
+2.78%
FAQ
What is Aptorum Group Ltd (APM) stock price today?
The current price of APM is 1.97 USD — it has decreased -11.06 % in the last trading day.
What is Aptorum Group Ltd (APM)'s business?
What is the price predicton of APM Stock?
What is Aptorum Group Ltd (APM)'s revenue for the last quarter?
What is Aptorum Group Ltd (APM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Aptorum Group Ltd (APM)'s fundamentals?
How many employees does Aptorum Group Ltd (APM). have?